Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001532 · ClinicalTrials.gov registry record
Role of Genetic Factors in the Development of Lung Disease
A clinical trial of Asthma and Cystic Fibrosis, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Recruiting
- Registry status
- 3,500
- Enrollment target
- 2
- Study locations
NCT00001532 is a study of Asthma and Cystic Fibrosis that is actively recruiting participants, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 3,500 participants, above the 1,554-participant average among 374 other Asthma trials with a reported enrollment target (125% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT00001532, a study of Asthma and Cystic Fibrosis, is actively recruiting participants, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- RECRUITING
- Registry status
- 3,500 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible for processes directly involved in different diseases affecting the lungs of patients and healthy volunteers. Optional CT Sub-study The standard CT scan will be compared to the low dose radiation CT scan for the 150 subjects enrolled in the sub-study to assess the variation between the two techniques. Specifically, the quantitative computer aided detection of lung CT abnormalities from LAM can be compared to assess whether low radiation dose CT exams is an alternative to conventional CT to monitor disease status. This optional sub-study will be offered to up to 100 adult subjects with lung disease and up to 50 children age 9 and older with CF. Children will not be enrolled in the optional CT sub-study unless they have had a standard CT scan for medical purposes to use in comparison. One additional low dose radiation CT scan of the chest may be done as part of this sub-study when these subjects have their next annual CT scan.
Conditions Studied
Study Locations (2)
Maryland
- Suburban Hospital - Bethesda
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,500 participants |
| Start Date | 1996-09-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001532
The ClinicalTrials.gov registry entry for NCT00001532 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,554-participant average among 374 other Asthma trials with a reported enrollment target (125% higher). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Asthma appearing as the primary indexed condition, and to 0 interventions.
NCT00001532 reports 2 study locations spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00001532 about?
NCT00001532 is a clinical study titled "Role of Genetic Factors in the Development of Lung Disease". This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible fo...
What is the current status of trial NCT00001532?
This trial is currently recruiting. The enrollment target is 3,500 participants. The study started on 1996-09-13.
What conditions does trial NCT00001532 study?
This clinical trial studies the following conditions: Asthma, Cystic Fibrosis, Pulmonary Fibrosis, Tuberous Sclerosis, Pulmonary Sarcoidosis.
Who is sponsoring clinical trial NCT00001532?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001532 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Innate Immunity in Allergic Asthma
RECRUITING
-
Automated Inhaler Monitoring for Asthma Medication Usage
RECRUITING · NA
-
Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology
RECRUITING
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.